Rizzani de Eccher Spa, active in Russia since 1984 with over 150 projects completed, on October 1, 2021, signed an EPC Contract for the construction of a greenfield turnkey blood fractionation facility for a potential value of approx. €350 million.
The client, Octapharma-Pharmimex LLC, will implement the technologies of its parent company Octapharma, a world leader in the blood plasma fractionation segment.
Demand of gamma-immunoglobulins for treatment of immunodeficiencies is constantly increasing also in the Russian Federation.
With the new facility, Octapharma-Pharmimex will localize the production and distribution of life-saving blood products within the Russian Federation, and thus reduce the need to import products from abroad.
It will be an advanced pharmaceutical facility, with classified clean rooms of A, B, C, D grades, air filtration and environmental monitoring in accordance with the sterile production requirements. Technology will be applied in accordance with the European and Russian standards for operations of this kind.
The new manufacturing facility, located in Ryazan Region, will consist of a production building including fractionation, purification and filling areas, warehouse for storage of plasma, laboratories, an administrative building as well as auxiliary utility buildings.
After five months of preconstruction engineering (Design Endorsement Phase), the construction works are planned to start in April 2022 and the full facility is to be commissioned in June 2026.